- Home
- AKTX vs NTIP Comparison
AKTX vs NTIP Comparison
Compare AKTX & NTIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKTX
- NTIP
- Stock Information
- Founded
- AKTX N/A
- NTIP 1990
- Country
- AKTX United States
- NTIP United States
- Employees
- AKTX N/A
- NTIP N/A
- Industry
- AKTX Biotechnology: Pharmaceutical Preparations
- NTIP Multi-Sector Companies
- Sector
- AKTX Health Care
- NTIP Miscellaneous
- Exchange
- AKTX Nasdaq
- NTIP Nasdaq
- Market Cap
- AKTX 29.5M
- NTIP 29.5M
- IPO Year
- AKTX N/A
- NTIP 1998
- Fundamental
- Price
- AKTX $0.99
- NTIP $1.29
- Analyst Decision
- AKTX
- NTIP
- Analyst Count
- AKTX 0
- NTIP 0
- Target Price
- AKTX N/A
- NTIP N/A
- AVG Volume (30 Days)
- AKTX 80.3K
- NTIP 17.9K
- Earning Date
- AKTX 02-15-2025
- NTIP 10-24-2024
- Dividend Yield
- AKTX N/A
- NTIP 7.58%
- EPS Growth
- AKTX N/A
- NTIP N/A
- EPS
- AKTX N/A
- NTIP N/A
- Revenue
- AKTX N/A
- NTIP $1,881,000.00
- Revenue This Year
- AKTX N/A
- NTIP N/A
- Revenue Next Year
- AKTX N/A
- NTIP N/A
- P/E Ratio
- AKTX N/A
- NTIP N/A
- Revenue Growth
- AKTX N/A
- NTIP 129.39
- 52 Week Low
- AKTX $0.90
- NTIP $1.24
- 52 Week High
- AKTX $4.40
- NTIP $2.25
- Technical
- Relative Strength Index (RSI)
- AKTX 31.38
- NTIP 45.22
- Support Level
- AKTX $0.95
- NTIP $1.25
- Resistance Level
- AKTX $1.13
- NTIP $1.37
- Average True Range (ATR)
- AKTX 0.15
- NTIP 0.05
- MACD
- AKTX 0.02
- NTIP -0.00
- Stochastic Oscillator
- AKTX 15.15
- NTIP 33.33
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property rights. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.